Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA

Geron Corporation (GERN) PT Raised to $6 at Goldman SachsJune 10, 2024 11:59 AM Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent AnemiaJune 6, 2024 9:58 PM